Terms ending in 2039
Every in-force patent on Takara Bio Inc.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,999,972 | Fibronectin Fragment to Be Used for Stem Cell Production In force · High confidence | Takara Bio Inc. | In force | High confidence | |
| US 11,572,580 | Oligonucleotide Preservation Method In force · High confidence | Takara Bio Inc. | In force | High confidence | |
| US 12,018,294 | DNA Polymerase Mutant Suited to Nucleic Acid Amplification from RNA In force · High confidence | Takara Bio Inc. | In force | High confidence | |
| US 12,359,177 | DNA Polymerase Mutant Suited to Nucleic Acid Amplification from RNA In force · High confidence | Takara Bio Inc. | In force | High confidence | |
| US 12,613,244 | Method for Rapid Accurate Dispensing, Visualization and Analysis of Single Cells In force · Low confidence | Takara Bio USA, Inc. | In force | Low confidence | |
| US 11,473,057 | Method for Obtaining Microglia from Pluripotent Stem Cells In force · Medium confidence | Takara Bio Inc. | In force | Medium confidence | |
| US 11,667,952 | Methods of Producing Nucleic Acids Using Oligonucleotides Modified by a Stimulus In force · High confidence | Takara Bio USA, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.